Cargando…

In vivo expansion and activation of γδ T cells as immunotherapy for refractory neuroblastoma: A phase 1 study

INTRODUCTION: CD3+ γδ+ T cells comprise 2% to 5% of circulating T cells with Vγ9Vδ2+ cells the dominant circulating subtype. Vγ9Vδ2+ cells recognize non-peptide phosphoantigens and stress-associated NKG2D ligands expressed on malignant cells. Strategies that incorporate the tumoricidal properties of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pressey, Joseph G., Adams, Julia, Harkins, Lualhati, Kelly, David, You, Zhiying, Lamb, Lawrence S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2016
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5265919/ https://www.ncbi.nlm.nih.gov/pubmed/27684826 http://dx.doi.org/10.1097/MD.0000000000004909

Ejemplares similares

CMV-Independent Lysis of Glioblastoma by Ex Vivo Expanded/Activated Vδ1+ γδ T Cells
por: Knight, Andrea, et al.
Publicado: (2013)

Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials
por: Jonus, Hunter C., et al.
Publicado: (2022)

Autologous or allogeneic hematopoietic stem cells transplantation combined with high-dose chemotherapy for refractory neuroblastoma: A protocol for systematic review and meta-analysis
por: Zhao, Zhang-Shuai, et al.
Publicado: (2021)

Characterization of Donor Variability for γδ T Cell ex vivo Expansion and Development of an Allogeneic γδ T Cell Immunotherapy
por: Burnham, Rebecca E., et al.
Publicado: (2020)

Remarkable response to anti-PD1 immunotherapy in refractory metastatic high-grade myxofibrosarcoma patient: A case report
por: Luo, Yi, et al.
Publicado: (2021)

Dynamics of Circulating γδ T Cell Activity in an Immunocompetent Mouse Model of High-Grade Glioma
por: Beck, Benjamin H., et al.
Publicado: (2015)

Bone and bone marrow involvement in neuroblastoma: A case report
por: Huang, Can, et al.
Publicado: (2020)

A novel clinical tool and risk stratification system for predicting the event-free survival of neuroblastoma patients: A TARGET-based study
por: Li, Mingzhen, et al.
Publicado: (2023)

Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model
por: Zoine, Jaquelyn T., et al.
Publicado: (2019)

Occult olfactory neuroblastoma presenting with multiple bone metastases: a case report
por: Zhou, Qi, et al.
Publicado: (2020)

Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification
por: Huang, Can, et al.
Publicado: (2020)

Apatinib plus retinoic acid as maintenance for children with relapsed stage 4 high-risk neuroblastoma: Two case reports
por: Jin, Mei, et al.
Publicado: (2020)

Efficacy and safety of bevacizumab treatment for refractory brain edema: Case report
por: Meng, Xiangying, et al.
Publicado: (2017)

A highly malignant case of neuroblastoma with substantial increase of single-nucleotide variants and normal mismatch repair system: A case report
por: Yuan, Lin-Qing, et al.
Publicado: (2017)

Successful treatment of refractory cancer pain with morphine and ropivacaine: A case report
por: Li, Hongyan, et al.
Publicado: (2017)

Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report
por: Zhou, Zhencang, et al.
Publicado: (2022)

Usefulness of (18)F-Fluorodeoxyglucose Positron Emission Tomography for Follow-Up of 13-cis-Retinoic Acid Treatment for Residual Neuroblastoma After Myeloablative Chemotherapy
por: Sato, Yuya, et al.
Publicado: (2015)

Prognostic value of neutrophil-to-lymphocyte ratio in peripheral blood and pathological tissue in patients with esophageal squamous cell carcinoma
por: Guo, Quanquan, et al.
Publicado: (2020)

The cardiotoxicity of cetuximab as single therapy in Chinese chemotherapy-refractory metastatic colorectal cancer patients
por: Tang, Xue-Miao, et al.
Publicado: (2017)

TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis
por: Qin, Jiqiu, et al.
Publicado: (2023)

Cuproptosis-related prognostic signatures predict the prognosis and immunotherapy in HCC patients
por: Peng, Hong, et al.
Publicado: (2023)

Chemotherapy efficacy after first-line immunotherapy in 18 advanced melanoma patients
por: Saint-Jean, Mélanie, et al.
Publicado: (2020)

Response to immunotherapy in a patient with anaplastic thyroid cancer: A case report
por: Zheng, Luming, et al.
Publicado: (2021)

The safety and efficacy of chemotherapy combined with immunotherapy for pancreatic cancer: A meta-analysis
por: Huang, Yang, et al.
Publicado: (2021)

Complete and long-lasting response to immunotherapy: A case report of urothelial cancer
por: Silva, Diogo J., et al.
Publicado: (2022)

Knowledge mapping of immunotherapy for thyroid cancer from 1980 to 2022: A review
por: Ding, Ran, et al.
Publicado: (2023)

Successful adoptive transfer and in vivo expansion of haploidentical γδ T cells
por: Wilhelm, Martin, et al.
Publicado: (2014)

Bibliometric and visualized analysis of the top-100 highly cited articles on immunotherapy for endometrial cancer
por: Zheng, Wanzhen, et al.
Publicado: (2023)

Comprehensive characterization of MUC16 mutations in lung adenocarcinoma for immunotherapies and prognosis: An observational study
por: Liu, Tingjun, et al.
Publicado: (2023)

Identification of cancer-associated fibroblasts signature for predicting the prognosis and immunotherapy response in hepatocellular carcinoma
por: Ye, Jianzhong, et al.
Publicado: (2023)

Local Control by Radiofrequency Thermal Ablation Increased Overall Survival in Patients With Refractory Liver Metastases of Colorectal Cancer
por: Yang, Po-Chih, et al.
Publicado: (2016)

US-guided percutaneous laser ablation of refractory metastatic retroperitoneal lesions: A care-compliant case report
por: Tian, Guo, et al.
Publicado: (2017)

Safety and efficacy of apatinib combined with iodine-125 in chemotherapy-refractory advanced lung cancer: A case report
por: Zhang, Yunchao, et al.
Publicado: (2020)

Orelabrutinib versus ibrutinib for patients with refractory/relapsed primary central nervous system lymphoma: An efficacy and safety analysis
por: Qiao, Lijiao, et al.
Publicado: (2023)

Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug
por: Tanaka, Yoshimasa, et al.
Publicado: (2018)

Iodine-125 radioactive particles antagonize hyperprogressive disease following immunotherapy: A case report
por: Yang, Ning, et al.
Publicado: (2020)

Construction of a pyroptosis-related lncRNAs signature for predicting prognosis and immunotherapy response in glioma
por: Huang, Qianrong, et al.
Publicado: (2023)

Successful chemotherapy with continuous immunotherapy for primary pulmonary endovascular epithelioid hemangioendothelioma: A case report
por: Guo, Wenliang, et al.
Publicado: (2023)

Immune-related risk prognostic model for clear cell renal cell carcinoma: Implications for immunotherapy
por: Chen, Ronghui, et al.
Publicado: (2023)

A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy
por: Hirasawa, Yuya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s7mjkbtfvh2reipmp34u2crg30